These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

88 related items for PubMed ID: 1355766

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. RISUG (reversible inhibition of sperm under guidance)--an antimicrobial as male vas deferens implant for HIV free semen.
    Guha SK.
    Med Hypotheses; 2005; 65(1):61-4. PubMed ID: 15893119
    [Abstract] [Full Text] [Related]

  • 4. Reversibility with sodium bicarbonate of styrene maleic anhydride, an intravasal injectable contraceptive, in male rats.
    Koul V, Srivastav A, Guha SK.
    Contraception; 1998 Oct; 58(4):227-31. PubMed ID: 9866004
    [Abstract] [Full Text] [Related]

  • 5. Sperm characteristics and teratology in rats following vas deferens occlusion with RISUG and its reversal.
    Lohiya NK, Suthar R, Khandelwal A, Goyal S, Ansari AS, Manivannan B.
    Int J Androl; 2010 Feb; 33(1):e198-206. PubMed ID: 19811546
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Preclinical evaluation for noninvasive reversal following long-term vas occlusion with styrene maleic anhydride in langur monkeys.
    Lohiya NK, Manivannan B, Mishra PK, Sriram S, Bhande SS, Panneerdoss S.
    Contraception; 2005 Mar; 71(3):214-26. PubMed ID: 15722073
    [Abstract] [Full Text] [Related]

  • 9. Histological changes in the vas deferens of rats after injection of a new male antifertility agent "SMA" and its reversibility.
    Sethi N, Srivastava RK, Singh RK.
    Contraception; 1990 Mar; 41(3):333-9. PubMed ID: 2323221
    [Abstract] [Full Text] [Related]

  • 10. Biophysical mechanism-mediated time-dependent effect on sperm of human and monkey vas implanted polyelectrolyte contraceptive.
    Guha SK.
    Asian J Androl; 2007 Mar; 9(2):221-7. PubMed ID: 17334590
    [Abstract] [Full Text] [Related]

  • 11. Phase II clinical trial of a vas deferens injectable contraceptive for the male.
    Guha SK, Singh G, Ansari S, Kumar S, Srivastava A, Koul V, Das HC, Malhotra RL, Das SK.
    Contraception; 1997 Oct; 56(4):245-50. PubMed ID: 9408706
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Safety evaluation of a male injectable antifertility agent, styrene maleic anhydride, in rats.
    Sethi N, Srivastava RK, Singh RK.
    Contraception; 1989 Feb; 39(2):217-26. PubMed ID: 2706990
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Developmental effects of petroleum creosote on mice following oral exposure.
    Iyer PR, Irvin TR, Martin JE.
    Res Commun Chem Pathol Pharmacol; 1993 Dec; 82(3):371-4. PubMed ID: 8122038
    [Abstract] [Full Text] [Related]

  • 17. Relative suitability of DMSO and NaHCO3 for reversal of RISUG® induced long-term contraception.
    Ansari AS, Hussain M, Khan SR, Lohiya NK.
    Andrology; 2016 Mar; 4(2):306-13. PubMed ID: 26748683
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.